# AEWS0031

Source: https://onco.cc/trials/aews0031/  
OnCo record `aews0031` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AEWS0031 showed that giving the same chemotherapy for Ewing sarcoma every two weeks instead of every three cured more patients without adding side effects, and the two-weekly schedule became the standard for localised disease in North America.

## Summary

AEWS0031 was a Children's Oncology Group phase 3 trial that randomised 587 patients (568 eligible, 284 per arm) with localised Ewing sarcoma to fourteen cycles of alternating vincristine, doxorubicin, cyclophosphamide and ifosfamide, etoposide given every 21 days or every 14 days with growth factor support. The primary endpoint was event-free survival.

The median cycle interval achieved was 21 days in the standard arm and 15 days in the intensified arm. Event-free survival at five years was 73 percent with interval compression against 65 percent with the standard schedule, with similar toxicity. Interval-compressed VDC/IE is the standard first-line regimen on the corpus's Ewing sarcoma page, alongside the European Euro Ewing 2012 result that reached the same conclusion.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-22
- Also known as: COG AEWS0031
- Tags: soc-trials
- Registry id: NCT00006734
- Phase: 3
- Setting: Localised Ewing sarcoma in patients under 50: fourteen cycles of alternating vincristine, doxorubicin and cyclophosphamide with ifosfamide and etoposide given every three weeks (standard) or every two weeks with filgrastim support (interval-compressed), around local control with surgery or radiotherapy
- Sponsor: Children's Oncology Group
- Enrolled: 587
- Result: Five-year event-free survival 73 percent with two-weekly (interval-compressed) chemotherapy against 65 percent with three-weekly chemotherapy (p 0.048), with similar toxicity.
- Outcomes: Event-free survival at 5 years: Interval-compressed VDC/IE every 14 days 73% vs Standard VDC/IE every 21 days 65%

## Sources

- ClinicalTrials.gov NCT00006734: https://clinicaltrials.gov/study/NCT00006734

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/), [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/), [Ifosfamide](https://onco.cc/drugs/ifosfamide/), [Vincristine](https://onco.cc/drugs/vincristine/)
- institutions: [Children's Oncology Group (COG)](https://onco.cc/institutions/childrens-oncology-group/)
- key papers: [AEWS0031: randomised trial of interval-compressed chemotherapy for localised Ewing sarcoma](https://onco.cc/key-papers/paper-aews0031-interval-compressed-chemotherapy-ewing-womer-jco-2012/)

---
JSON: https://onco.cc/api/v1/entities/aews0031.json